

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 2 of 26

Currently Pending Claims:

The currently pending claims are reiterated for the convenience of the Examiner.

Claims 1-12 (canceled)

13. (Previously presented) A compound of formula II:




II

or a pharmaceutically acceptable salt thereof; wherein:

one L is selected from the group consisting of:

(a) a moiety of formula XI:



wherein

each R_v is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy and substituted thioalkoxy;

R_v is a covalent bond linking the moiety to the linker;

each R_w is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy and substituted thioalkoxy;

Q_6 is NR_w , O, S or alkylene, where R_w is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or acyl;

Best Available Copy


Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 3 of 26

Q_6 is NR_v , O, S or alkylene, where R_v is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or acyl;
each m is independently an integer from 1 to 3;

(b) a moiety of formula XII:



XII

wherein


each R_x is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl and heterocyclic;

R_y is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl;

R_z is a covalent bond linking the moiety to the linker;

E is CH or N; and

(c) a moiety of formula XIII:



XIII

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 4 of 26

wherein

each R_{aa} is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl and heterocyclic;


R_{ab} is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, thioalkoxy, substituted thioalkoxy, wherein the alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, thioalkoxy or substituted thioalkoxy group is substituted with a covalent bond linking the moiety to the linker;

D is a covalent bond, NR_{ab} , O or S, where R_{ab} is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or acyl;

E is CH or N;

and the other L is selected from the group consisting of:

- (d) a moiety of formula XI;
- (e) a moiety of formula XII;
- (f) a moiety of formula XIII;
- (g) a moiety of formula VI:



VI

wherein

each R_j is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl and a covalent bond linking the moiety to the linker;

R_k is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, hydroxy, halogen and -CHO;

Application Serial No.: 10/824,005


Attorney Docket No. P-082-US3

Page 5 of 26

each Q_2 is independently NR_j , O and S, where R_j is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or acyl;

provided one and only one of R_j comprises a covalent bond linking the moiety to the linker;

(h) a moiety of formula VIII:



wherein


each R_o is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy and substituted thioalkoxy;

R_p is aryl or heteroaryl, wherein the aryl or heteroaryl group is substituted with a covalent bond linking the moiety to the linker or with $-OZ'$ where Z' is a covalent bond linking the moiety to the linker;

Z is 2H or O;

m is an integer from 1 to 3;

(i) a moiety of formula IX:



wherein

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 6 of 26

each R_q is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl, heterocyclic and a covalent bond linking the moiety to the linker;


each R_q is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl and acyl;

R_s is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl and acyl;

R_r is aryl or heteroaryl, wherein the aryl or heteroaryl group is substituted with a covalent bond linking the moiety to the linker;

provided one and only one of R_q or R_r comprises a covalent bond linking the moiety to the linker;

(j) a moiety of formula X:



wherein

each R_q is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy and substituted thioalkoxy;

each R_q is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl,

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 7 of 26


heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy, substituted thioalkoxy and a covalent bond linking the moiety to the linker;

Q_5 is NR_t , O, S or alkylene, where R_t is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or acyl;

each m is independently an integer from 1 to 3;

provided one and only one of R_u comprises a covalent bond linking the moiety to the linker;

(k) a moiety of formula XIV:




wherein

R_{ac} is a covalent bond linking the moiety to the linker;

R_{ad} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl and heterocyclic;

R_{ae} is aryl or heteroaryl;

(l) a moiety of formula XV:



wherein

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 8 of 26

R_{af} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl and acyl;

each R_{ag} is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy and substituted thioalkoxy;


R_{ah} is aryl or heteroaryl;

R_{ai} is aryl or heteroaryl, wherein the aryl or heteroaryl group is substituted with a covalent bond linking the moiety to the linker;

Q_7 is NR_{af} , O, S or alkylene, where R_{af} is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or acyl;

m' is 1 or 2;

(m) a moiety of formula XVI:



wherein

each R_{aj} is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy and substituted thioalkoxy;

R_{ai} is aryl or heteroaryl;

each R_{ak} is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 9 of 26


substituted cycloalkyl, aryl, heteroaryl, heterocyclic, and a covalent bond linking the moiety to the linker;

Q_8 is $NR_{al'}$, O, S or alkylene, where $R_{al'}$ is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or acyl;

m is an integer from 1 to 3;

provided one and only one of R_{ak} comprises a covalent bond linking the moiety to the linker;

(n) a moiety of formula XIX:



wherein

R_{as} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl and a covalent bond linking the moiety to the linker;

R_{at} is selected from the group consisting of 4-phosphonomethylphenyl, 4-phosphonodifluoromethylphenyl, 3-carboxy-4-carboxymethoxyphenyl and 3,4-dihydroxyphenyl;

R_{au} is aryl or heteroaryl, wherein the aryl or heteroaryl group is substituted with a covalent bond linking the moiety to the linker or with $-OZ'$, where Z' is a covalent bond linking the moiety to the linker;

R_{av} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl and alkaryl;


provided one and only one of R_{as} and R_{au} comprises a covalent bond linking the moiety to the linker;

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 10 of 26

(o) a moiety of formula XX:



wherein


each R_{aw} is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy and substituted thioalkoxy;

each R_{ax} is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy, substituted thioalkoxy, a covalent bond linking the moiety to the linker and -OZ', where Z' is a covalent bond linking the moiety to the linker;

each m is independently an integer from 1 to 3;

provided one and only one of R_{ax} comprises a covalent bond linking the moiety to the linker;

(p) a moiety of formula XXIV:



wherein


R_{be} is a covalent bond linking the moiety to the linker;

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 11 of 26


(q) a moiety of formula XXVI:



wherein

 R_{bi} is a covalent bond linking the moiety to the linker;

(s) a moiety of formula XXVII:



wherein

each R_{bj} is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl and a covalent bond linking the moiety to the linker;

Q_{11} is NR_{bj} , O, S or alkylene, where R_{bj} is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or acyl;


provided one and only one of R_{bj} comprises a covalent bond linking the moiety to the linker;

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 12 of 26

(t) a moiety of formula XXVIII:




wherein

each R_{bk} is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aminoacyloxy, aryl, carboxyl, carboxyalkyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, heterocyclic, hydroxy, oxyacylamino, nitro, thioalkoxy, substituted thioalkoxy, $-SO-R_{bk}$, and $-SO_2-R_{bk}$, where R_{bk} is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl or heterocyclic;

R_{bl} is aryl or heteroaryl, wherein the aryl or heteroaryl group is substituted with a covalent bond linking the moiety to the linker or with $-(CH_2)_u-Z'$, where Z' is a covalent bond linking the moiety to the linker and u is an integer from 1 to 3;

m is an integer from 1 to 3; and

(u) a moiety of formula XXIX:



wherein

R_{bn} is selected from the group consisting of alkoxy, substituted alkoxy, hydroxy and $-OZ'$, where Z' is a covalent bond linking the moiety to the linker;

R_{bo} is aryl or heteroaryl;

R_{bp} is acyl, alkoxy-carbonyl and a covalent bond linking the moiety to the linker;


Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 13 of 26

provided one and only one of R_{bn} and R_{bp} comprises a covalent bond linking the moiety to the linker;

and each X is a linker independently selected from a group of the formula:



wherein

m' is an integer of from 0 to 20;

X^a at each separate occurrence is selected from the group consisting of -O-, -S-, -NR-, -C(O)-, -C(O)O-, -C(O)NR-, -C(S)-, -C(S)O-, -C(S)NR- or a covalent bond;

Z is at each separate occurrence is selected from the group consisting of alkylene, substituted alkylene, cycloalkylene, substituted cycloalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, heteroarylene, heterocyclene, or a covalent bond;

Y^a and Y^b at each separate occurrence are selected from the group consisting of: -C(O)NR'-, -NR'C(O)-, -NR'C(O)NR'-, -C(=NR')-NR'-, -NR'-C(=NR')-, -NR'-C(O)-O-, -N=C(R)-NR'-, -P(O)(OR')-O-, -S(O)_nCR'R"-, -S(O)_n-NR'-, -S-S- and a covalent bond; where n is 0, 1 or 2; and

R, R' and R" at each separate occurrence are selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and heterocyclic.

14. (Previously presented) The compound of Claim 13, wherein one or both ligands are a moiety of formula XI.

15. (Previously presented) The compound of Claim 13, wherein one or both ligands are a moiety of formula XII.

16. (Previously presented) The compound of Claim 13, wherein one or both ligands are a moiety of formula XIII.


Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 14 of 26

17. (Previously presented) The compound of Claim 13, wherein one L is selected from the group consisting of:

(a) a moiety of formula O:




wherein

R₂₆ is selected from the group consisting of hydrogen and acyl;

Het₁ is heterocyclic or heteroaryl;

(b) a moiety of formula P:



wherein

R₂₇ is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and substituted alkyl;


Ar₃ is aryl; and

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 15 of 26

(c) a moiety of formula S:



wherein

D is selected from the group consisting of a covalent bond, -NH-, -S- and -O-;

E is selected from the group consisting of CH and N;

Ar₃ is aryl;


and the other L is selected from the group consisting of:

(d) a moiety of formula O;

(e) a moiety of formula P;

(f) a moiety of formula S;

(g) a moiety of formula D:



wherein


R₆ is selected from the group consisting of substituted alkyl and -CHO;R₇ is selected from the group consisting of hydrogen, alkyl and acyl;

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 16 of 26

(h) a moiety of formula F:



wherein

R_{10} is selected from the group consisting of hydrogen, alkoxy, amino and substituted amino;


R_{11} is selected from the group consisting of hydrogen, alkoxy, halogens, amino, substituted amino and nitro;

R_{12} is selected from the group consisting of hydrogen, hydroxy, alkoxy and halogen;

R_{13} is selected from the group consisting of hydrogen, hydroxy, alkoxy and halogen;

Z is selected from the group consisting of 2H and O;

(i) a moiety of formula H:



wherein

R_{17} and R_{18} are independently selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms;


Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3


Page 17 of 26

R₁₉ is selected from the group consisting of alkyl of 1 to 6 carbon atoms, CH₂C(O)OEt, -(CH₂)₃OH, alkaryl, aryl and heteroaryl;

(j) a moiety of formula N:



(k) a moiety of formula U:



wherein

R₂₉ is selected from the group consisting of 4-pyrimidinyl, 2-methylaminopyrimidin-4-yl, 2-phenoxy pyrimidin-4-yl, 2-(4-methoxyphenoxy)pyrimidin-4-yl, 2-(4-fluorophenoxy)pyrimidin-4-yl, 2-(4-aminocarbonylphenoxy)pyrimidin-4-yl, 2-(4-ethylphenoxy)pyrimidin-4-yl, 2-(4-benzyloxyphenoxy)pyrimidin-4-yl, 2-(4-cyanophenoxy)pyrimidin-4-yl, 2-(4-hydroxyphenoxy)pyrimidin-4-yl, 2-(3-methoxyphenoxy)pyrimidin-4-yl, 2-(4-phenylphenoxy)pyrimidin-4-yl, 2-(4-phenoxyphenoxy)pyrimidin-4-yl, 2-(3-hydroxyphenoxy)pyrimidin-4-yl, 2-(2-hydroxyphenoxy)pyrimidin-4-yl, 2-(3,4-methylenedioxyphenoxy)pyrimidin-4-yl, 2-(3-fluorophenoxy)pyrimidin-4-yl, 2-(2-fluorophenoxy)pyrimidin-4-yl, 2-(2-methoxyphenoxy)pyrimidin-4-yl, 2-(3-trifluoromethylphenoxy)pyrimidin-4-yl, 2-(3,4-difluorophenoxy)pyrimidin-4-yl,


Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 18 of 26

2-(4-methylsulfonylphenoxy)pyrimidin-4-yl, 2-(4-methoxyphenoxy)pyrimidin-4-yl, 4-pyridinyl, 2-phenoxy pyridin-4-yl, 2-(4-methoxyphenoxy)pyridin-4-yl, 2-(4-fluorophenoxy)pyridin-4-yl, 2-(4-benzyloxyphenoxy)pyrimidin-4-yl, 2-(4-cyanophenoxy)pyrimidin-4-yl, 2-(4-hydroxyphenoxy)pyrimidin-4-yl, 2-(3-methoxyphenoxy)pyrimidin-4-yl, 2-(4-phenylphenoxy)pyrimidin-4-yl, 2-(4-phenoxyphenoxy)pyrimidin-4-yl, 2-(3-hydroxyphenoxy)pyrimidin-4-yl, 2-(2-hydroxyphenoxy)pyrimidin-4-yl, 2-(3,4-methylenedioxyphenoxy)pyrimidin-4-yl, 2-(3-fluorophenoxy)pyrimidin-4-yl, 2-(2-fluorophenoxy)pyrimidin-4-yl, 2-(2-methoxyphenoxy)pyrimidin-4-yl, 2-(3-trifluoromethylphenoxy)pyrimidin-4-yl, 2-(3,4-difluorophenoxy)pyrimidin-4-yl, 2-(4-methylsulfonylphenoxy)pyrimidin-4-yl, and 2-(4-methoxyphenoxy)pyrimidin-4-yl;

(I) a moiety of formula V:



wherein

R_{30} is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, halogen and alkoxy;

R_{31} is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, halogen, alkoxy and Z_v ;


R_{32} is selected from the group consisting of hydrogen, amino, substituted amino, alkoxy, $-NHCOCH_3$, and Z_v , provided one and only one of R_{31} and R_{32} is Z_v ;

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 19 of 26

(m) a moiety of formula Z:




wherein

R₃₄ is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halogen and substituted alkyl;


R₃₅ is selected from the group consisting of hydrogen and halogen;

R₃₆, R₃₇, and R₃₈ are selected from the group consisting of hydrogen, -NO₂, alkyl, substituted alkyl, amino, substituted amino, alkoxy, hydroxy and halogen;

(n) a moiety of formula L:



(o) a moiety of formula M:



wherein, in formula L and M,


Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 20 of 26

R₂₂ is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and substituted alkyl;


R₂₃ is



R₂₄ is selected from the group consisting of hydrogen and acyl;


R₂₅ is selected from the group consisting of alkyl and cycloalkyl;

R₃₉ is selected from the group consisting of



Ar₂ is selected from the group consisting of alkyl of 1 to 6 carbon atoms, substituted alkyl and aryl;

(p) a moiety of formula Q:




(q) a moiety of formula AA:


Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3


Page 21 of 26




(r) a moiety of formula X:



(s) a moiety of formula Y:



(t) a moiety of formula AB:




(u) a moiety of formula AH:


Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3


Page 22 of 26



(v) a moiety of formula AI:



(w) a moiety of formula AB':



wherein

R_{41} is independently selected from the group consisting of hydrogen, 4-CH₃, 5-CH₃ and 4,5-di-CH₃;

R_{42} is independently selected from the group consisting of hydrogen, CH₃, -F, -Cl and -NO₂;

R_{49} is independently selected from the group consisting of acetyl, t-BOC, -Cbz, and -C(O)Ph;

R_{50} is independently selected from the group consisting of C₁₋₅ alkyl;

Ar_5 is independently selected from the group consisting of C₆H₅, p-C₆H₄OH, and other substituted phenyl groups;

u is an integer from 1 to 3,

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 23 of 26

and further wherein $Z_d, Z_f, Z_h, Z_l, Z_m, Z_n, Z_o, Z_p, Z_q, Z_s, Z_u, Z_v, Z_x, Z_y, Z_z, Z_{aa}, Z_{ab}, Z_{ah},$
and Z_{ai} are covalent bonds linking the moiety to the linker;
and stereoisomers thereof.

18. (Previously presented) The compound of Claim 17, wherein one L is a moiety of formulae O, P, or S, and the other L is a moiety of formulae D, F, H, N, O, P, S, U, V, or Z.
19. (Previously presented) The compound of Claim 17, wherein one L is a moiety of formulae O, P, or S, and the other L is a moiety of formulae L or M.
20. (Previously presented) The compound of Claim 17, wherein one L is a moiety of formulae O, P, or S, and the other L is a moiety of formula Q.
21. (Previously presented) The compound of Claim 17, wherein one L is a moiety of formulae O, P, or S, and the other L is a moiety of formula AA.
22. (Previously presented) The compound of Claim 17, wherein one L is a moiety of formulae O, P, or S, and the other L is a moiety of formulae X or Y.
23. (Previously presented) The compound of Claim 17, wherein one L is a moiety of formulae O, P, or S, and the other L is a moiety of formulae AB, AH, or AI.
24. (Previously presented) The compound of Claim 17, wherein one or both L is a moiety of formulae O.
25. (Previously presented) The compound of Claim 17, wherein one or both L is a moiety of formulae P.
26. (Previously presented) The compound of Claim 17, wherein one or both L is a moiety of formulae S.

Application Serial No.: 10/824,005

Attorney Docket No. P-082-US3

Page 24 of 26

27. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 13.
28. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 17.
29. (canceled)
30. (Previously presented) A method of treating a disease or medical disorder mediated by a protein kinase wherein the disease or medical disorder is selected from the group consisting of recurrent ocular herpetic keratitis, diabetic retinopathy, VEGF-induced angiogenesis, macular degeneration, ischemia, atherosclerosis, and psoriasis, the method comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 13.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.